Your Must-Know Guide Before You Take: Vyvgart
In Your Must-Know Guide Before You Take: Vyvgart, readers will embark on a journey through the latest advancements in the treatment of generalized myasthenia gravis (gMG), a rare autoimmune disorder that severely impairs muscle strength and daily functioning. This book offers a thorough examination of gMG, outlining its debilitating symptoms such as muscle weakness, swallowing difficulties, and fatigue, and the profound impact these symptoms can have on patients' lives. By setting the stage with a clear understanding of gMG, the book provides a critical foundation for exploring novel treatment approaches.
The book introduces Vyvgart (efgartigimod), a groundbreaking biologic therapy that received FDA approval in December 2021, as a revolutionary option for managing severe gMG. Vyvgart's innovative mechanism of action targets the neonatal Fc receptor (FcRn), specifically reducing harmful IgG autoantibodies that disrupt nerve-muscle communication. This targeted approach marks a significant departure from traditional treatments and offers new hope for patients who have not found relief with conventional therapies.
Detailed chapters cover Vyvgart's administration, dosage, and clinical efficacy, providing readers with an in-depth look at how this therapy performs in real-world settings. The book discusses the pivotal ADAPT trial and compares Vyvgart with other biologics and traditional treatments, highlighting its unique benefits and long-term potential for improving patient outcomes. This comprehensive analysis offers a valuable perspective for those seeking to understand how Vyvgart fits into the broader landscape of gMG treatment.
Lastly, the book addresses practical considerations for patients, including administration logistics, side effects management, and the challenges of accessibility due to cost and insurance coverage. It also explores the future of gMG treatment, with a focus on ongoing research and the potential impact of biosimilars. By providing a detailed, up-to-date examination of Vyvgart and its role in advancing gMG care, this book serves as an essential resource for patients, caregivers, and healthcare professionals alike.
1147444777
The book introduces Vyvgart (efgartigimod), a groundbreaking biologic therapy that received FDA approval in December 2021, as a revolutionary option for managing severe gMG. Vyvgart's innovative mechanism of action targets the neonatal Fc receptor (FcRn), specifically reducing harmful IgG autoantibodies that disrupt nerve-muscle communication. This targeted approach marks a significant departure from traditional treatments and offers new hope for patients who have not found relief with conventional therapies.
Detailed chapters cover Vyvgart's administration, dosage, and clinical efficacy, providing readers with an in-depth look at how this therapy performs in real-world settings. The book discusses the pivotal ADAPT trial and compares Vyvgart with other biologics and traditional treatments, highlighting its unique benefits and long-term potential for improving patient outcomes. This comprehensive analysis offers a valuable perspective for those seeking to understand how Vyvgart fits into the broader landscape of gMG treatment.
Lastly, the book addresses practical considerations for patients, including administration logistics, side effects management, and the challenges of accessibility due to cost and insurance coverage. It also explores the future of gMG treatment, with a focus on ongoing research and the potential impact of biosimilars. By providing a detailed, up-to-date examination of Vyvgart and its role in advancing gMG care, this book serves as an essential resource for patients, caregivers, and healthcare professionals alike.
Your Must-Know Guide Before You Take: Vyvgart
In Your Must-Know Guide Before You Take: Vyvgart, readers will embark on a journey through the latest advancements in the treatment of generalized myasthenia gravis (gMG), a rare autoimmune disorder that severely impairs muscle strength and daily functioning. This book offers a thorough examination of gMG, outlining its debilitating symptoms such as muscle weakness, swallowing difficulties, and fatigue, and the profound impact these symptoms can have on patients' lives. By setting the stage with a clear understanding of gMG, the book provides a critical foundation for exploring novel treatment approaches.
The book introduces Vyvgart (efgartigimod), a groundbreaking biologic therapy that received FDA approval in December 2021, as a revolutionary option for managing severe gMG. Vyvgart's innovative mechanism of action targets the neonatal Fc receptor (FcRn), specifically reducing harmful IgG autoantibodies that disrupt nerve-muscle communication. This targeted approach marks a significant departure from traditional treatments and offers new hope for patients who have not found relief with conventional therapies.
Detailed chapters cover Vyvgart's administration, dosage, and clinical efficacy, providing readers with an in-depth look at how this therapy performs in real-world settings. The book discusses the pivotal ADAPT trial and compares Vyvgart with other biologics and traditional treatments, highlighting its unique benefits and long-term potential for improving patient outcomes. This comprehensive analysis offers a valuable perspective for those seeking to understand how Vyvgart fits into the broader landscape of gMG treatment.
Lastly, the book addresses practical considerations for patients, including administration logistics, side effects management, and the challenges of accessibility due to cost and insurance coverage. It also explores the future of gMG treatment, with a focus on ongoing research and the potential impact of biosimilars. By providing a detailed, up-to-date examination of Vyvgart and its role in advancing gMG care, this book serves as an essential resource for patients, caregivers, and healthcare professionals alike.
The book introduces Vyvgart (efgartigimod), a groundbreaking biologic therapy that received FDA approval in December 2021, as a revolutionary option for managing severe gMG. Vyvgart's innovative mechanism of action targets the neonatal Fc receptor (FcRn), specifically reducing harmful IgG autoantibodies that disrupt nerve-muscle communication. This targeted approach marks a significant departure from traditional treatments and offers new hope for patients who have not found relief with conventional therapies.
Detailed chapters cover Vyvgart's administration, dosage, and clinical efficacy, providing readers with an in-depth look at how this therapy performs in real-world settings. The book discusses the pivotal ADAPT trial and compares Vyvgart with other biologics and traditional treatments, highlighting its unique benefits and long-term potential for improving patient outcomes. This comprehensive analysis offers a valuable perspective for those seeking to understand how Vyvgart fits into the broader landscape of gMG treatment.
Lastly, the book addresses practical considerations for patients, including administration logistics, side effects management, and the challenges of accessibility due to cost and insurance coverage. It also explores the future of gMG treatment, with a focus on ongoing research and the potential impact of biosimilars. By providing a detailed, up-to-date examination of Vyvgart and its role in advancing gMG care, this book serves as an essential resource for patients, caregivers, and healthcare professionals alike.
1.99
In Stock
5
1
Your Must-Know Guide Before You Take: Vyvgart
Your Must-Know Guide Before You Take: Vyvgart
eBook
$1.99
Related collections and offers
1.99
In Stock
Product Details
| BN ID: | 2940184502786 |
|---|---|
| Publisher: | Unity Ink |
| Publication date: | 05/18/2025 |
| Series: | Your Must-Know Guide Before You Take |
| Sold by: | Barnes & Noble |
| Format: | eBook |
| File size: | 20 MB |
| Note: | This product may take a few minutes to download. |
About the Author
From the B&N Reads Blog